Dalmia Bharat Sugar and Industries Full Year 2025 Earnings: Beats Expectations

Dalmia Bharat Sugar and Industries (NSE:DALMIASUG) Full Year 2025 Results

Key Financial Results

• Revenue: ₹37.5b (up 29% from FY 2024).
• Net income: ₹3.87b (up 42% from FY 2024).
• Profit margin: 10% (in line with FY 2024).
• EPS: ₹47.78 (up from ₹33.66 in FY 2024).

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Dalmia Bharat Sugar and Industries Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 4.7%. Earnings per share (EPS) also surpassed analyst estimates by 52%.

The primary driver behind last 12 months revenue was the Sugar segment contributing a total revenue of ₹30.4b (81% of total revenue). Notably, cost of sales worth ₹27.9b amounted to 74% of total revenue thereby underscoring the impact on earnings. The largest operating expense was General & Administrative costs, amounting to ₹2.29b (39% of total expenses). Over the last 12 months, the company's earnings were enhanced by non-operating gains of ₹91.4m. Explore how DALMIASUG's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 7.6% p.a. on average during the next 2 years, compared to a 9.6% growth forecast for the Food industry in India.

Performance of the Indian Food industry.

The company's shares are down 2.7% from a week ago.

Risk Analysis

It's still necessary to consider the ever-present spectre of investment risk. We've identified 1 warning sign with Dalmia Bharat Sugar and Industries, and understanding this should be part of your investment process.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.